| Thomas, Michael |
ELENA, NCT05560646: A Study to Investigate Efficacy and Safety of OG-6219 BID in 3 Dose Levels Compared With Placebo in Participants Aged 18 to 49 With Moderate to Severe Endometriosis-related Pain |
|
|
| Active, not recruiting | 2 | 380 | Europe, US, RoW | OG-6219, Placebo | Organon and Co, Iqvia Pty Ltd | Endometriosis | 05/25 | 05/25 | | |
| Recruiting | 2 | 340 | Europe, Japan, US, RoW | Pembrolizumab, Dostarlimab, GSK4057190, Belrestotug, EOS884448, GSK4428859A, Nelistotug, GSK6097608 | GlaxoSmithKline, iTeos Therapeutics | Lung Cancer, Non-Small Cell | 10/25 | 10/28 | | |
NCT04318938: Advancing Brigatinib Properties in ALK+ NSCLC Patients by Deep Phenotyping |
|
|
| Active, not recruiting | 2 | 118 | Europe | Brigatinib, Study treatment, Tyrosine kinase inhibitor | Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest, Thoraxklinik-Heidelberg gGmbH, Takeda | NSCLC | 01/26 | 01/26 | | |
| Recruiting | N/A | 656 | US | Ovaprene | Daré Bioscience, Inc., Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) | Contraception | 06/25 | 09/25 | | |
| Recruiting | N/A | 700 | Europe, Canada, US, RoW | | EMD Serono Research & Development Institute, Inc., Merck KGaA, Darmstadt, Germany | Cancer | 03/27 | 03/27 | | |
| Kreuter, Michael |
| Active, not recruiting | 3 | 160 | Europe, Canada, Japan, US, RoW | Molgramostim, Recombinant human granulocyte-macrophage colony stimulating factor (rhGM-CSF), Placebo | Savara Inc., Savara ApS, | Autoimmune Pulmonary Alveolar Proteinosis | 11/23 | 11/24 | | |
BEconneCTD-ILD, NCT06572384: A Study of the Efficacy and Safety of Belimumab in Adults With Interstitial Lung Disease Associated With Connective Tissue Disease |
|
|
| Recruiting | 3 | 440 | Europe, Japan, US, RoW | Belimumab, BENLYSTA, GSK1550188, Placebo | GlaxoSmithKline | Lung Diseases, Interstitial | 10/28 | 12/28 | | |
| Completed | 2 | 81 | Europe, Canada, US, RoW | Garadacimab, Factor XIIa antagonist monoclonal antibody, CSL312, Placebo | CSL Behring | Idiopathic Pulmonary Fibrosis | 01/24 | 01/24 | | |
| Herth, Felix JF |
| Active, not recruiting | 3 | 1667 | Europe, Canada, Japan, US, RoW | GSK3511294 (Depemokimab), Mepolizumab, Benralizumab, Placebo, Standard of care (SoC), Pre-filled Syringes (PFS) | GlaxoSmithKline, Iqvia Pty Ltd | Asthma | 10/25 | 10/25 | | |
|
NCT06317285: A Study to Evaluate the Efficacy and Safety of GSK3915393 in Participants With Idiopathic Pulmonary Fibrosis (IPF) |
|
|
| Recruiting | 2 | 150 | Europe, Canada, US, RoW | GSK3915393, Placebo | GlaxoSmithKline | Idiopathic Pulmonary Fibrosis | 03/26 | 03/26 | | |
NCT03685526: Cinenses Lung Volume Reduction Reverser System First-in-man Study Treating Patients With Severe Emphysema |
|
|
| Active, not recruiting | N/A | 15 | Europe | Cinenses Lung Volume Reduction Reverser System | Lifetech Scientific (Shenzhen) Co., Ltd. | Emphysema | 10/21 | 08/22 | | |
| Completed | N/A | 102 | Europe, RoW | AeriSeal, Zephyr Valves, Bronchoscopic Lung Volume Reduction (BLVR), Zephyr System | Pulmonx Corporation | Emphysema, COPD, Severe Emphysema | 10/23 | 10/24 | | |
NCT06035120: An Evaluation of the AeriSeal System for CONVERTing Collateral Ventilation Status in Patients with Severe Emphysema |
|
|
| Recruiting | N/A | 200 | Europe, US, RoW | AeriSeal System | Pulmonx Corporation | Emphysema, Pulmonary, Emphysema or COPD | 06/27 | 03/28 | | |
IAB-1, NCT05087641: A Multicenter, Prospective Trial of the IAB in Adults Suffering From COPD/Emphysema |
|
|
| Active, not recruiting | N/A | 20 | Europe, RoW | IAB System | Pulmair Medical, Inc. | Emphysema, Pulmonary Disease, Chronic Obstructive | 04/24 | 01/27 | | |
RheSolve, NCT04677465: Clinical Study of the RheOx Bronchial Rheoplasty System in Treating the Symptoms of Chronic Bronchitis |
|
|
| Active, not recruiting | N/A | 270 | Europe, US | RheOx Bronchial Rheoplasty, Sham Procedure | Gala Therapeutics, Inc. | Chronic Bronchitis | 05/24 | 10/25 | | |
| Active, not recruiting | N/A | 464 | Europe, US | Targeted Lung Denervation (TLD), TLD, TLD Therapy, Optimal Medical Care | Nuvaira, Inc. | COPD | 10/24 | 09/28 | | |
| Recruiting | N/A | 100 | Europe | RheOx | Gala Therapeutics, Inc. | Chronic Bronchitis, COPD | 12/24 | 12/25 | | |
| Recruiting | N/A | 300 | Europe | Bronchoscopic Thermal Vapor Ablation, BTVA, InterVapor | Uptake Medical Technology, Inc. | Emphysema or COPD | 12/27 | 12/30 | | |
| Al-Batran, Salah-Eddin |
| Completed | 3 | 430 | Europe | Ramucirumab, TAS 102 | Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest, Eli Lilly and Company, Trium Analysis Online GmbH | Colorectal Cancer | 07/24 | 07/24 | | |
| Completed | 2 | 50 | Europe | Lenvatinib, Study treatment, Nivolumab | Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest, Bristol-Myers Squibb, Eisai GmbH | Advanced Hepatocellular Carcinoma | 10/22 | 05/23 | | |
NCT03530267: Aflibercept and 5-FU vs. FOLFOX as 1st Line Treatment for Elderly or Frail Elderly Patients With Met. Colorectal Cancer |
|
|
| Completed | 2 | 124 | Europe | Aflibercept + mLV5FU2, mFOLFOX7 | Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest, STABIL - Statistische und Biometrische Lösungen, Trium Analysis Online GmbH, Sanofi | Colorectal Cancer | 02/24 | 02/24 | | |
NCT06440993: Durvalumab + Intraductal Radiofrequency Ablation (ID-RFA) in Extrahepatic Cholangiocarcinoma |
|
|
| Recruiting | 2 | 42 | Europe | Gemcitabine, Cisplatin, Durvalumab, ID-RFA | Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest, Universitätsklinikum Düsseldorf, Germany, Universitätsklinikum Köln, Germany, AstraZeneca | Extrahepatic Cholangiocarcinoma, Unresectable Perihilar or Ductal CCA | 01/27 | 04/28 | | |
NCT05101629 / 2021-000355-40: Pembrolizumab and Lenvatinib in Patients With Advanced HCC Who Are Refractory to Atezolizumab and Bevacizumab/ IO-based Therapy |
|
|
| Active, not recruiting | 2 | 32 | Europe | Pembrolizumab, Keytruda, Lenvatinib Capsules, Lenvima | Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest, Medizinische Hochschule Hannover, Germany, Prof. Dr. Arndt Vogel, Merck Sharp & Dohme LLC | Hepatocellular Carcinoma | 01/25 | 12/25 | | |
IMMUWIN, NCT04522544: Durvalumab and Tremelimumab in Combination With Either Y-90 SIRT or DEB-TACE for Intermediate Stage HCC |
|
|
| Recruiting | 2 | 55 | Europe | Tremelimumab, Durvalumab, Y-90 SIRT, DEB-TACE | Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest, AstraZeneca, Hannover Medical School | Hepatocellular Carcinoma Non-resectable, HCC | 03/25 | 09/25 | | |
NCT04511455: Cabozantinib for Patients with Hepatocellular Carcinoma (HCC) Refractory to First Line Treatment |
|
|
| Completed | 2 | 22 | Europe | Cabozantinib | Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest, Ipsen | Hepatocellular Carcinoma Non-resectable, Metastatic Hepatocellular Carcinoma | 12/24 | 12/24 | | |
NCT05565794: Pemigatinib After Curative Local Therapy in Advanced iCCA With FGFR2 Fusion/Rearrangements |
|
|
| Recruiting | 2 | 20 | Europe | Pemigatinib, Pemazyre | Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest, Incyte Biosciences International Sàrl | Intrahepatic Cholangiocarcinoma, FGFR2 Gene Mutation, FGFR2 Gene Rearrangement, FGFR2 Gene Translocation | 11/25 | 11/26 | | |
| Recruiting | 2 | 50 | Europe | Durvalumab, Other Name: MEDI4736, Tremelimumab, Study treatment | Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest, AstraZeneca | Intrahepatic Cholangiocarcinoma | 12/25 | 12/25 | | |
NCT04318938: Advancing Brigatinib Properties in ALK+ NSCLC Patients by Deep Phenotyping |
|
|
| Active, not recruiting | 2 | 118 | Europe | Brigatinib, Study treatment, Tyrosine kinase inhibitor | Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest, Thoraxklinik-Heidelberg gGmbH, Takeda | NSCLC | 01/26 | 01/26 | | |
| Recruiting | 2 | 674 | Europe | Atezolizumab, TECENTRIQ, 5-Fluorouracil, 5-FU, Calciumfolinat, Leucovorin, Oxaliplatin, ELOXATIN, Docetaxel, TAXOTERE | Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest, Roche Pharma AG | Gastric Cancer, Gastroesophageal Junction Adenocarcinoma | 05/27 | 12/27 | | |
R-Pola-Glo, NCT05798156: Rituximab in Combination with Glofitamab and Polatuzumab Vedotin in Patients with Previously Untreated Aggressive B-cell Lymphoma Ineligible for R-CHOP |
|
|
| Recruiting | 2 | 125 | Europe | Glofitamab, Rituximab, Obinutuzumab, Polatuzumab vedotin | Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest, Charite University, Berlin, Germany, University of Salzburg, Arbeitsgemeinschaft medikamentoese Tumortherapie, Roche Pharma AG, Zentrum für Klinische Studien Leipzig, Hoffmann-La Roche | Lymphoma, Large B-Cell, Diffuse | 04/25 | 09/28 | | |
NCT05825625: NeoTRACK - Dissection of IO Efficacy in NSCLC by Longitudinal tracKing |
|
|
| Recruiting | 2 | 35 | Europe | Atezolizumab, Tecentriq, Tiragolumab, no other name available | Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest, Thoraxklinik-Heidelberg gGmbH, Roche Pharma AG | Non-small Cell Lung Cancer | 11/29 | 02/30 | | |
PARAGON, NCT04119362: Platform for Outcome, Quality of Life, and Translational Research on Pancreatic Cancer |
|
|
| Completed | N/A | 469 | Europe | Quality of live questionnaires, Optional translational project | Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest, Celgene | Pancreatic Adenocarcinoma | 06/23 | 06/23 | | |
| Completed | N/A | 400 | Europe | FoundationOne®CDx and FoundationOne®Liquid | Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest, Roche Pharma AG | Hepatocellular Cancer, Cholangiocarcinoma, Gallbladder Cancer, Pancreatic Cancer, Oesophageal Cancer, Stomach Cancer | 08/24 | 08/24 | | |
PROTraSarc, NCT06050434: Prospective Study to Evaluate Patient Reported Outcomes (PRO) During Rechallenge With Trabectedin in Sarcoma Patients |
|
|
| Completed | N/A | 7 | Europe | | Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest, PharmaMar | Soft Tissue Sarcoma | 07/24 | 07/24 | | |
| Bozorgmehr, Farastuk |
ANTELOPE, NCT05689671: Pemetrexed-free vs. Pemetrexed-based Immunochemotherapy in Metastatic TTF-1 Negative Lung Adenocarcinoma |
|
|
| Recruiting | 4 | 136 | Europe | Atezolizumab, Tecentriq, Nab paclitaxel, Abraxane, Carboplatin, Pembrolizumab, Keytruda, Cisplatin, Pemetrexed | Nikolaj Frost MD, Roche Pharma AG, Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest | Non-Small Cell Lung Cancer Metastatic | 10/25 | 10/26 | | |
| Recruiting | 3 | 560 | Europe, Canada, Japan, US, RoW | sigvotatug vedotin, SGN-B6A; PF-08046047, docetaxel | Seagen Inc. | Carcinoma, Non-Small-Cell Lung | 07/26 | 07/28 | | |
| Completed | 2 | 68 | Europe | Atezolizumab, thoracic radiotherapy (TRT) | Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest, Thoraxklinik-Heidelberg gGmbH, Roche Pharma AG | Small Cell Lung Cancer Extensive Stage, Thoracic Radiotherapy | 09/24 | 09/24 | | |
| Recruiting | 2 | 88 | Europe | Durvalumab Injection [Imfinzi], Thoracic Radiotherapy (TRT) conventionally, Thoracic Radiotherapy (TRT) hypofractionated | Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest, Thoraxklinik-Heidelberg gGmbH, AstraZeneca | NSCLC, Stage III | 10/25 | 06/26 | | |
| Active, not recruiting | 2 | 67 | Europe | Atezolizumab | Technische Universität Dresden, Roche Pharma AG | Large Cell Neuroendocrine Carcinoma of the Lung | 01/28 | 01/29 | | |
| Grünewald, Christiane |
| No trials found |
| Ralf, Eberhardt |
| No trials found |
